Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Real Time Quote from BATS)
$35.31 USD
+1.28 (3.76%)
Updated Aug 8, 2024 01:44 PM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
GPCR 35.31 +1.28(3.76%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GPCR
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
IPO Round Up of First Half of 2023
Other News for GPCR
Buy Rating Affirmed: Undervalued Structure Therapeutics Poised for Growth with Strong R&D Pipeline and Strategic Partnerships
3 Biotech Stocks That Could Make Your Summer Unforgettable
Viking sends Lilly, Novo lower as obesity drug enters late-stage program
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Piper Sandler
Roche Is Raising The Efficacy Bar For The Oral GLP-1 Drug Class